Abstract
The Alliance Scholar address briefly reviews nicotine, the biology of addiction, and the association of nicotine, depression, and the endocannabinoid system to tobacco dependence. Moreover, the latest management options for treating nicotine dependence are reviewed which include the Food and Drug Administration's (FDA) approved nicotine replacement therapies (i.e., nicotine polacrilex (2 mg and 4 mg), nicotine transdermal patch, the nicotine nasal spray, the nicotine oral inhaler, and the nicotine lozenge). In addition, the only non-nicotine smoking management option approved by the FDA is also discussed (i.e., bupropion SR, an anti-depressant). Finally, two investigational drugs (rimonabant and varenicline) currently being evaluated for treating nicotine dependence are briefly reviewed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
